Chloe Delepine
Seminars
Wednesday 7th October 2026
Panel Discussion: Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact
3:10 pm
- How to determine when a biomarker‑enabled strategy truly advances the program, balancing scientific risk, portfolio focus, and capital efficiency?
- What can biotech do to evaluate partnership models that foster innovation while ensuring operational feasibility, sustainable costs, and long-term scalability of CDx?
- When to integrate biomarker considerations into early clinical development without overburdening trial design, patient recruitment, or organizational capacity?
Thursday 8th October 2026
Integrating Multimodal Baseline Biomarkers with Clinical Outcomes in Patients with Cold, Refractory Tumors, Treated with Fc-Enhanced Anti–CTLA-4 Antibody Therapy
11:30 am
- Botensilimab (BOT), a novel Fcenhanced anti–CTLA-4 antibody, alone or combined with balstilimab (BAL; anti– PD-1), has demonstrated promising clinical activity across immunologically “cold” treatment-refractory cancers
- We assessed systemic, tumor, and clinical features of patients treated with BOT±BAL for metastatic treatment-refractory cancers in the phase 1 C-800-01 trial (NCT03860272)
- In cold and treatment-refractory cancers, clinical outcomes with BOT±BAL appear to depend on the balance between detrimental systemic inflammation and beneficial TME immune activity plus peripheral T-cell differentiation, rather than conventional single biomarkers
